glp-1 alternative Drug Savings: A Complete Guide for How to Save on Ozempic, Wegovy, and More NotCo Uses AI to Create

In the past ten years, a series of Phase III trials showed that the synthetic GLP-1/GIP agonists are effective in lowering blood sugar in type 2 diabetic subjects who were both treatment-nave or on typical first-line therapies such as metformin and insulin

The challenge is to support innovation while maintaining clinical standards and patient protection

Carefully selecting WRCs as follow-on/lead indications to gain reimbursement across markets where weight loss is unlikely to get covered, developing well thought out go-to-market strategy including direct-to-consumer and digital health models, and ensuring there is adequate manufacturing capacity to meet demand are also critical to success

Neurology 96 , e2920e2932 (2021)

doi: 10.2337/dc15-0843

A New Predictive Equation for Resting Energy Expenditure in Healthy Individuals